Long-Term Outcomes After Lorlatinib vs Crizotinib in Patients With Advanced ALK-Positive NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
J. Clin. Oncol 2024 May 31;[EPub Ahead of Print], BJ Solomon, G Liu, E Felip, TSK Mok, RA Soo, J Mazieres, AT Shaw, F de Marinis, Y Goto, YL Wu, DW Kim, JF Martini, R Messina, J Paolini, A Polli, D Thomaidou, F Toffalorio, TM BauerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.